Abstract

Background Many studies on the genetic background of common neoplastic diseases indicate that they may be the result of hereditary mutations in cancer susceptibility genes, such as BRCA1, CHEK2, CDKN2A, NOD2, NBS1. The cancer occurrence in genetically predisposed mutation carriers may be a matter of life expectancy, efficiency of the immunological system, and cumulative action of toxic environmental agents. Most cytostatic drugs used in the treatment of cancers in oncological wards have mutagenic and carcinogenic activity. The exposure to them is difficult to avoid by the medical staff in their daily work during preparation and administration of drugs as well as during the contact with patients (physical examination, nursing care).

Highlights

  • Many studies on the genetic background of common neoplastic diseases indicate that they may be the result of hereditary mutations in cancer susceptibility genes, such as BRCA1, CHEK2, CDKN2A, NOD2, NBS1

  • A constitutional mutation was found in 24% persons: NOD2(3020insC) in 10.7%, CDKN2A(A148T) in 6.7%, CHEK2(I157T) in 5.3%, and CHEK2(IVS2+1G®A) in 1.3%

  • The frequency of NOD2(3020insC), CDKN2A (A148T), CHEK2(I157T) and CHEK2(IVS2 1®G) was significantly higher than in general Polish population (10.7% vs. 7.3%; 6.7% vs. 3.5%; 5.3% vs. 4.8% and 1.3% vs. 0.48%, respectively)

Read more

Summary

Introduction

Constitutional mutations of cancer susceptibility genes in the health workers professionally exposed to cytostatic drugs Background Many studies on the genetic background of common neoplastic diseases indicate that they may be the result of hereditary mutations in cancer susceptibility genes, such as BRCA1, CHEK2, CDKN2A, NOD2, NBS1. Most cytostatic drugs used in the treatment of cancers in oncological wards have mutagenic and carcinogenic activity.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call